Hemodynamic change in patients with hypertrophic obstructive cardiomyopathy before and after alcohol septal ablation using 4D flow magnetic resonance imaging: a retrospective observational study

Kenichiro Suwa1*, Keitaro Akita1*, Keisuke Iguchi1, Takasuke Ushio2 and Yuichiro Maekawa1

Abstract

Background: The hemodynamics in the left ventricle (LV) and the ascending aorta (AAO) before and after alcohol septal ablation (ASA) in patients with hypertrophic obstructive cardiomyopathy (HOCM) is elucidated. Our objective was to evaluate the pattern changes in AAO and intra-LV flow assessed by four-dimensional (4D) flow magnetic resonance imaging (MRI) before and after ASA and to clarify the association between 4D flow MRI-derived hemodynamic characteristics and the peak pressure gradient (PPG) in patients with drug-refractory HOCM.

Methods: In this retrospective observational study, 11 patients with HOCM underwent 4D flow MRI before and a week after ASA. The 4D flow MRI included blood flow visualization and quantification using streamline images. The combined score of vortex and helix in AAO was analyzed. The duration and phase count of the AAO vortex or helix flow and the size of the intra-LV anterior vortex were quantified. The correlation between the changes in hemodynamics and the resting PPG at LV outflow tract was also analyzed. We used the paired t-test for the comparison between before and after ASA and the Pearson’s correlation coefficient for the analysis.

Results: The combined score for the incidence of vortex and/or helix flow in AAO after ASA was significantly lower than that before ASA (1.45 ± 0.52 vs. 1.09 ± 0.30, p = 0.046). The duration (744 ± 291 ms vs. 467 ± 258 ms, p < 0.001) and phase count (14.8 ± 4.4 phases vs. 10.5 ± 5.8 phases, p < 0.001) of the vortex or helix flow in AAO were significantly decreased after ASA. The LV anterior vortex area after ASA was significantly larger than that before ASA (1628 ± 420 mm² vs. 2974 ± 539 mm², p = 0.009). The delta phase count of the AAO vortex or helix before and a week after ASA was significantly correlated with delta PPG before and a week after ASA (R = 0.79, p = 0.004) and with delta PPG before and 6 months after ASA (R = 0.83, p = 0.002).

Conclusions: Lower vortex or helix flow in AAO and larger diastolic vortex flow in LV were observed after ASA, which suggests the possibility to detect the changes of aberrant hemodynamics in HOCM.

Keywords: 4D flow MRI, Alcohol septal ablation, Hemodynamics, Hypertrophic obstructive cardiomyopathy
(HCM) [1–3]. The relief of obstruction improves the short- or long-term prognosis of HCM [4, 5]. Alcohol septal ablation (ASA) is a method of reducing LVOTO and alleviating heart failure symptoms in patients with hypertrophic obstructive cardiomyopathy (HOCM) [6–8]. There is some evidence that ascending aorta (AAO) flow is disease-specific in valvular heart disease and cardiomyopathy [9–12]. Four-dimensional (4D) flow magnetic resonance imaging (MRI) can demonstrate that flow derangement in AAO can be frequently observed in patients with HOCM compared to healthy volunteers and may also be associated with the severity of LVOTO [13]. 4D flow MRI can also achieve flow visualization and quantification in AAO, and evaluate aortic hemodynamics in high spatial and temporal resolutions [14]. Therefore, in the present study, we aimed to evaluate the pattern changes in AAO and intra-left ventricular flow before and after ASA and to elucidate the association between 4D flow MRI-derived hemodynamic characteristics and the LVOT peak pressure gradient (PPG) in patients with drug-refractory HOCM.

Methods

Patients

This retrospective observational study included 18 patients diagnosed with HOCM by transthoracic echocardiography (TTE) in our institute from February 1, 2018 to May 31, 2020. The patient selection is presented in Fig. 1. All patients underwent ASA for drug-refractory HOCM. HOCM is defined as a maximum left ventricle (LV) thickness ≥ 15 mm or ≥ 13 mm with a family history of HCM and LV cavity obliteration with a pressure gradient > 30 mmHg at rest or under provocation by TTE [15]. Four patients who had cardiac implantable electrical devices (CIED) compatible only with a 1.5T MRI scanner were excluded from the analysis because a 3T scanner was required for 4D flow MRI in our institute. Patients with concomitant mid-ventricular obstruction were also excluded. As a result, the initial 4D flow MRI analysis was performed in 13 patients with HOCM scheduled for ASA. Follow-up cardiac MRI a week after ASA was cancelled for two patients who required pacemaker or implantable cardioverter defibrillator implantation because of sustained complete atrioventricular block and/or ventricular tachycardia, which are contraindications for MRI examination. Finally, 11 patients who underwent cardiac MRI before and a week after ASA were included in the study. This study complied with the principles of Declaration of Helsinki and was approved by the Ethics Committee of Hamamatsu University School of Medicine. All patients provided written informed consent.

Transthoracic echocardiography

All patients underwent TTE for the initial evaluation of HOCM and the assessment of the intervention in a week and six months (6 M) after ASA. TTE parameters included LV end-diastolic dimension (LVEDD), LV end-systolic dimension (LVESD), maximum interventricular septal thickness (Max-IVST), left atrial dimension (LAD), left atrial volume index (LAVI), resting PPG at LVOT, the incidence of moderate or severe mitral regurgitation (MR), and the length of the anterior and posterior leaflets of the mitral valve. The systolic anterior motion (SAM) of the mitral valve leaflet was evaluated according to the following grading: G0, without SAM; G1, no mitral leaflet-septal contact with a systolic minimum distance > 10 mm; G2, no mitral leaflet-septal contact with a systolic minimum distance < 10 mm; G3, brief mitral leaflet-septal contact; and G4, prolonged mitral leaflet-septal contact [16]. The anterior and posterior leaflets of the mitral valve were also measured during TTE before ASA.

Cardiac MRI

Cardiac MRI (Discovery MR750 or MR750w, GE Healthcare, Waukesha, USA) was performed for all patients before and a week after ASA with a maximum gradient strength of 50 mT/m (MR750) or 44 mT/m (MR750w) and a maximum slew rate of 200 mT/m/ms (both MR750
and MR750w). A commercially available 32-channel phased array body coil for MR750, or the geometry embedding method phased array coil for MR750w were applied. For the clinical purposes of assessment of chamber size and extent of scar, two-dimensional (2D) fast imaging employing steady-state acquisition (FIESTA) based on a steady-state free precession sequence for cine images and inversion recovery prepared fast gradient echo sequence for late gadolinium enhancement (LGE) images were acquired in the short, vertical long-axis and horizontal long-axis orientations with a slice thickness/gap of 10 mm/0 mm. A bolus injection of 0.1 mmol/kg gadobutrol (Gadovist, Bayer AG, Berlin, Germany) using a power injector (Sonic Shot GX, Nemoto Kyorindo Co., Tokyo, Japan) was administered at an injection rate of 2.0 mL/s followed by 20 mL of saline at the same injection rate.

Conventional cardiac MRI
Conventional cardiac MRI images were analyzed using Cardiac VX (GE Healthcare, Waukesha, USA). Max-IVST in diastole (Max-IVSTd) and systole (Max-IVSTs), LV end-diastolic and LV end-systolic volume indices (LVEDVI and LVESVI), LV stroke volume index (LVSVI), LV ejection fraction (LVEF), LV mass index (LVMI), right ventricular (RV) end-diastolic and RV end-systolic volume index (RVEDVI and RVESVI), and RV ejection fraction (RVEF) were quantified using short-axis images of 2D FIESTA. Papillary muscles and trabeculations were included in the blood pool. LGE mass and a fraction of LGE to LV mass (%LGE) were analyzed by measuring regions with signal intensity > 6 standard deviations (SD) above the nullled remote myocardium. Whole lesions with microvascular obstruction were manually included in the LGE mass.

4D flow MRI acquisitions
Retrospective electrocardiography-gated 4D flow MRI data were acquired using a respiratory navigator with full volumetric coverage of the whole heart and ascending thoracic aorta. The imaging parameters for 4D flow MRI were as follows: repetition time (TR): 4.7 ms, echo time (TE): 2.4 ms, flip angle (FA): 15°, number of excitations (NEX): 4, field of view (FOV): 32–36 cm, matrix of 224 × 224, thickness: 2 mm, partitions: 60, phases during one cardiac cycle: 20, velocity sensitivity (VENC): 550 cm/s, and receiver bandwidth (RBW): 62.5 kHz. The data were reconstructed using autocalibrating reconstruction for Cartesian sampling with a reduction factor of 2 on a personal computer (Intel Xeon E3-1270 [3.4 GHz/Quad-core] DDR3, 16GB ECC, Linux). For geometric information for 4D flow MRI, multiphase contrast-enhanced 3D fast spoiled gradient recalled acquisition in the steady state (FSPGR) MR angiography (MRA) was performed just after injection of contrast medium and before LGE scan. Imaging parameters for coronal MRA were as follows: TR: 3.2 ms, TE: 1 ms, FA: 12°, NEX: 1, FOV: 32–36 cm, size of the reconstructed matrix with the aid of zero-fill interpolation: 512, RBW: 83.3 kHz, and imaging time: 33 s for four phases.

4D flow MRI postprocessing
4D flow MRI and 3D FSPGR MRA datasets were formatted by digital imaging and communications in medicine for postprocessing. The 3D segmentation of heart and vessel structure and visualization and quantification of hemodynamic measurements for 4D flow MRI were performed using Flova (R’-Tech, Hamamatsu, Japan). The regions of interest, including the LA, LV, and thoracic aorta, were determined at the R wave peak using the region-growing method. Their shapes were rendered by the marching-cubes method. The 3D flow information was interpolated with a spatial resolution of 2 × 2 × 2 mm using 3D datasets. Three-D streamline images with a cardiac cycle divided into 20 phases were created using the Runge–Kutta method to visualize and quantify hemodynamics.

Hemodynamic assessment by 4D flow MRI
Aorta flow patterns were evaluated by the presence of vortex or helix flow, i.e., point 1 for the presence and point 0 for absence. Vortex flow was defined as revolving particles around an axis orthogonal to the vessel centerline. Helix flow was defined as rotational motion around the longitudinal axis of the vessel centerline. The combined measurement of vortex and helix existence (Vortex + Helix) was also calculated as the sum of the points. We also measured the duration and phase count of the vortex and/or helix flow within a cardiac cycle (Fig. 2). In patients with a vortex in the aorta, the area of the vortex was measured. As shown in Fig. 3, the 3D wall shear stress (WSS) at peak systole in the AAO from the ST junction to the origin of the brachiocephalic artery was quantified for the outer (WSS_outer) and inner curvature of the aortic arch (WSS_inner). For the intra-LV hemodynamics, diastolic LV inflow was visualized, and the presence of a concomitant vortex ring was investigated. LV inflow was observed from the left lateral side of the heart. Both the anterior vortex generated above the mitral valve rotated clockwise (Fig. 4a and b, white circle) and the posterior vortex generated below the mitral valve rotated in a counterclockwise direction (Fig. 4a, white arrow) were evaluated to determine whether they were present or not. The maximum area of the diastolic LV vortex observed from the left lateral side was also quantified. We evaluated systolic LV outflow and the presence of vortex
Fig. 2 Serial streamline images in ascending aorta before and a week after ASA. The vortex flow (white arrows) appeared in the mid-ascending aorta in the late systole to early diastole both before (a) and a week after ASA (b). In images before ASA, the vortex flow changed to helix flow (yellow arrows) at mid diastole and continued to late diastole (a). In contrast, the vortex or helix flow disappeared in mid to late diastole after ASA (b). The cardiac phases started from early systole (phase 1) and ended at late diastole (phase 20). Abbreviation: ASA, alcohol septal ablation
flow just above LVOT (Fig. 4c, yellow arrow). LV outflow was observed from the anterior side of the heart (Fig. 4c and d). To assess the association between hemodynamic parameters and severity of HOCM, the differences in 4D flow MRI-derived hemodynamic parameters before and a week after ASA were calculated and compared with the difference in LVOT PPG. The 4D flow MRI analysis was repeated in all patients by a second observer (K.A.) independently for the assessment of interobserver variabilities. The determination of the presence of vortex and helix in AAO and the vortex size in AAO and LV were performed independently.

**Statistical analysis**
Continuous data are expressed as means ± SD for normal distribution or as medians with interquartile ranges for non-normal distribution. Categorical data are shown as numbers and percentages. For the comparison between before and after ASA, the paired t-test for normal distribution and the Wilcoxon signed-rank test for non-normal distribution were used. Categorical data were compared using Fisher’s exact test. The Pearson’s correlation coefficient was calculated for correlation analysis. The interobserver variabilities for the determination of the presence of vortex and helix in AAO, systolic vortex above LVOT, the vortex size in AAO, and diastolic LV vortex size were evaluated by calculating Cohen’s kappa coefficient or intraclass correlation coefficients (ICC). All statistical analyses were performed using SPSS statistics, version 25 (IBM Corporation, Armonk, NY, USA).

**Results**

**Baseline characteristics and details of the procedure characteristics**
The baseline characteristics of the participants are listed in Table 1. The raw data are shown in Additional file 1: Table S1. The mean age was 67 ± 12 years, and 72.7% of all patients were women. The prevalence of a family history of HCM and paroxysmal atrial fibrillation was 27.3% and 18.2%, respectively. Details of the procedure characteristics are listed in Table 2. Resting LVOT PPG decreased 6 M after ASA (108.7 ± 68.8 mmHg before ASA vs. 28.0 ± 19.0 mmHg 6 M after ASA, p = 0.014). No deaths or strokes were observed, although two patients had a transient complete atrioventricular block complication during hospitalization. New York Heart Association (NYHA) class III or IV heart failure 6 M after ASA (7 [63.6%] before ASA vs.1 [9.1%] after ASA, p = 0.024)
and the serum N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) level 6 M after ASA (1610.5 [211.0–5060.0] pg/mL before ASA vs. 315.0 [266.0–1035.0] pg/mL after ASA, $p = 0.003$) were significantly improved compared to those before ASA. Concerning TTE variables, Max-IVST by TTE was significantly reduced 6 M after ASA (17.6 ± 4.4 mm vs. 16.2 ± 3.9 mm, $p = 0.008$). SAM grades 6 M after ASA were significantly mitigated compared to those before ASA (G0 [9.1%], G1 [0.0%], G2 [9.1%], G3 [45.4%], and G4 [36.3%] before ASA vs. G0 [9.1%], G1 [18.2%], G2 [63.6%], G3 [0.0%], and G4 [9.1%] after ASA, $p = 0.006$), while the other parameters demonstrated no change.

**Parameters of cine MRI before and after ASA**

As summarized in Table 3, Max-IVSTd and Max-IVSTs were significantly reduced in a week after ASA compared to before (Max-IVSTd: 19.3 ± 4.7 mm before ASA vs. 18.3 ± 4.6 mm after ASA, $p = 0.001$; Max-IVSTs: 22.0 ± 4.7 mm before ASA vs. 20.9 ± 4.5 mm after ASA, $p = 0.003$). LVEF was significantly reduced at a week after ASA compared to before (72.5 ± 9.4% before ASA vs. 65.2 ± 10.7% after ASA, $p = 0.033$), whereas LVEDVI, LVESVI, LVMi, RVEDVI, RVESVI, and RVEF did not show significant change. A larger LGE mass ($p = 0.001$) and %LGE ($p < 0.001$) were observed after ASA.
### Table 1 Baseline characteristics

| Number of patients | n = 11 |
|--------------------|--------|
| Age, years         | 67.2 ± 12.2 |
| Male, n (%)        | 3 (27.3) |
| BMI, kg/m²         | 22.4 ± 2.5 |
| NYHA class III or IV, n (%) | 7 (63.6) |
| Syncope, n (%)     | 1 (9.1) |
| Hypertension, n (%)| 4 (36.4) |
| Diabetes mellitus, n (%) | 0 (0.0) |
| Dyslipidemia, n (%) | 4 (36.4) |
| COPD, n (%)        | 0 (0.0) |
| Stroke, n (%)      | 0 (0.0) |
| Syncope, n (%)     | 1 (9.1) |
| Family history of SCD, n (%) | 1 (9.1) |
| Family history of HCM, n (%) | 3 (27.3) |
| Medication         |        |
| Na channel blockers, n (%) | 8 (72.7) |
| Beta blockers, n (%) | 10 (90.9) |
| Calcium channel antagonists, n (%) | 7 (63.6) |
| ACE-I/ARBs, n (%)  | 1 (9.1) |
| Amiodarones, n (%) | 1 (9.1) |
| OACs, n (%)        | 2 (18.2) |
| Laboratory data    |        |
| NT-proBNP, pg/mL   | 1610.5 (211.0–5060.0) |

#### Echocardiographic variables

| LVDD, mm               | 41.4 ± 4.0 |
|------------------------|------------|
| LVESD, mm              | 24.6 ± 3.8 |
| Max-IVST, mm           | 17.6 ± 4.4 |
| LAD, mm                | 40.5 ± 5.1 |
| LAVI, mL/m²            | 58.8 ± 16.9 |
| Resting LVOT PPG, mmHg | 108.7 ± 68.8 |
| Moderate or severe MR, n (%) | 7 (63.6) |
| Anterior leaflet length of MV, mm | 25.9 ± 4.7 |
| Posterior leaflet length of MV, mm | 17.4 ± 4.0 |

#### SAM grade of MV

| G0, n (%) | 1 (9.1) |
| G1, n (%) | 0 (0.0) |
| G2, n (%) | 1 (9.1) |
| G3, n (%) | 5 (45.4) |
| G4, n (%) | 4 (36.3) |

### Table 1 (continued)

#### Procedure characteristics and in-hospital outcomes

| Procedure | | |
|-----------|-----------|-----------|
| Number of injected septal arteries | 2.5 ± 1.3 |
| Volume of ethanol, mL | 4.1 ± 2.0 |
| Peak CK, IU/L | 1543.5 ± 436.3 |

#### In-hospital outcomes

| Death, n (%) | 0 (0.0) |
| VT/VF, n (%) | 0 (0.0) |
| Complete AV block, n (%) | 2 (18.2) |
| New CIED implantation, n (%) | 0 (0.0) |
| Stroke, n (%) | 0 (0.0) |
| Cardiac tamponade, n (%) | 0 (0.0) |
| New atrial fibrillation, n (%) | 0 (0.0) |

### Table 2 Procedure characteristics and in-hospital outcomes

#### Data are expressed as mean ± standard deviation or number (%)

| AV, atrioventricular; CIED, cardiac implantable electrical device; CK, creatine kinase; VT, ventricular fibrillation; VT, ventricular tachycardia |
|--------------------|------------------|----------------|-------------------|-------------------|
| Procedure | | In-hospital outcomes | | |
| | | Death, n (%) | VT/VF, n (%) | Complete AV block, n (%) | New CIED implantation, n (%) | Stroke, n (%) | Cardiac tamponade, n (%) | New atrial fibrillation, n (%) | |
| | | 0 (0.0) | 0 (0.0) | 2 (18.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |

### Table 3 Cine and LGE MRI and MRA before and 1 week after the ASA

#### Data are expressed as mean ± standard deviation

| Cine MRI | Before ASA | After ASA | p |
|----------|------------|-----------|---|
| Max-IVSTd, mm | 19.3 ± 4.3 | 18.3 ± 4.6 | 0.001 |
| Max-IVSTS, mm | 22.0 ± 4.7 | 20.9 ± 4.5 | 0.003 |
| LVEDVI, mL/m² | 76.3 ± 9.3 | 82.3 ± 25.1 | 0.337 |
| LVESVI, mL/m² | 21.0 ± 6.9 | 29.3 ± 15.8 | 0.083 |
| LVEF, % | 72.5 ± 9.4 | 65.2 ± 10.7 | 0.033 |
| LVMI, g/m² | 95.3 ± 27.6 | 97.5 ± 30.2 | 0.65 |
| RVEDVI, mL/m² | 48.1 ± 8.2 | 53.3 ± 12.1 | 0.26 |
| RVEF, % | 68.1 ± 12.4 | 65.9 ± 11.1 | 0.55 |
| LGE MRI | | | |
| LGE mass, g | 17.4 ± 17.7 | 38.3 ± 26.7 | 0.001 |
| %LGE, % | 10.3 ± 6.0 | 22.6 ± 8.4 | <0.001 |
| 3D MRA | | | |
| AAO-D, mm | 36.9 ± 7.5 | 36.6 ± 7.3 | 0.22 |
| AAO-DI, mm/m² | 23.9 ± 6.0 | 23.9 ± 5.9 | 0.82 |

#### Data are expressed as mean ± standard deviation

| %LGE, a fraction of late gadolinium enhancement to left ventricle mass; AAO-D, ascending aortic diameter; AAO-DI, ascending aortic diameter index; ASA, alcohol septal ablation; LGE, late gadolinium enhancement; LVEDVI, left ventricular end-diastolic volume index; LVEF, left ventricular ejection fraction; LVEDVI, left ventricular end-systolic volume index; RVEF, right ventricular ejection fraction; RVESVI, right ventricular end-systolic volume index |
| | | | |
| %LGE, a fraction of late gadolinium enhancement to left ventricle mass | | | |
| AAO-D, ascending aortic diameter | ASC, ascending aortic diameter index | ASA, alcohol septal ablation | LGE, late gadolinium enhancement | LVEDVI, left ventricular end-diastolic volume index | LVEF, left ventricular ejection fraction | LVEDVI, left ventricular end-systolic volume index | LVEF, left ventricular ejection fraction | RVEF, right ventricular ejection fraction | RVESVI, right ventricular end-systolic volume index |
Table 4  Characteristics of blood flow in the ascending aorta before and after ASA

| Case | Vortex | Helix | V + H | Vortex area, mm² | Vortex/Helix duration, ms | Vortex/Helix phase count, phases |
|------|--------|-------|-------|------------------|---------------------------|---------------------------------|
|      | Before ASA | After ASA | Before ASA | After ASA | Before ASA | After ASA | Before ASA | After ASA | Before ASA | After ASA | Before ASA | After ASA | Before ASA | After ASA | Before ASA | After ASA |
| 1    | 1       | 1      | 1      | 1      | 2           | 2           | 5398        | 5477       | 818     | 405       | 18        | 9        |
| 2    | 1       | 1      | 0      | 0      | 1           | 1           | 8716        | 9464       | 1118    | 842       | 19        | 16       |
| 3    | 1       | 1      | 0      | 0      | 1           | 1           | 3724        | 3193       | 509     | 170       | 9         | 3        |
| 4    | 1       | 0      | 1      | 1      | 2           | 1           | 1804        | 0          | 1213    | 762       | 19        | 15       |
| 5    | 1       | 0      | 0      | 1      | 1           | 1           | 7896        | 0          | 608     | 515       | 15        | 12       |
| 6    | 1       | 1      | 1      | 0      | 2           | 1           | 5989        | 6062       | 657     | 600       | 15        | 12       |
| 7    | 1       | 0      | 1      | 1      | 2           | 1           | 9691        | 7037       | 706     | 507       | 17        | 15       |
| 8    | 1       | 1      | 0      | 0      | 1           | 1           | 16,244      | 15,230     | 1097    | 761       | 20        | 20       |
| 9    | 1       | 1      | 0      | 0      | 1           | 1           | 3742        | 5218       | 463     | 162       | 9         | 5        |
| 10   | 1       | 1      | 0      | 0      | 1           | 1           | 7145        | 6836       | 304     | 140       | 8         | 3        |
| 11   | 1       | 1      | 1      | 0      | 2           | 1           | 10,139      | 7488       | 688     | 278       | 14        | 5        |

ASA, alcohol septal ablation; V + H, vortex + helix
Ascending aortic flow and intra-left ventricular flow patterns before and after ASA

Figures 2 and 4 show a representative case of changes in AAO and intra-LV flow patterns before and after ASA (Additional file 2–7: Movies 1–6). The characteristics of blood flow in the AAO and the LV in each patient are presented in Tables 4 and 5. As summarized in Table 6, vortex and helix flow patterns in AAO were less observed after ASA (1.45 ± 0.52 before ASA vs. 1.09 ± 0.30 after ASA, p = 0.046); however, the incidence of sole vortex or helix flow patterns did not significantly decrease after ASA. The duration as well as phase count of vortex and helix flow patterns in AAO shortened after ASA (duration: 744 ± 291 ms before ASA vs. 467 ± 258 ms after ASA, p < 0.001; phase count: 14.8 ± 4.4 phases before ASA vs. 10.5 ± 5.8 phases after ASA, p < 0.001). Regarding the comparison of intra-LV flow patterns before and after ASA, the diastolic anterior vortex area after ASA was larger than that before ASA (1628 ± 420 mm² before ASA vs. 2974 ± 539 mm² after ASA, p = 0.009); however, there were no significant changes in the diastolic posterior vortex area after ASA. The incidence of systolic vortex flow just above the LVOT showed a significant decrease after ASA compared to that before ASA (63.6% before ASA vs. 9.1% after ASA, p = 0.014). There were no changes in WSSouter (p = 0.575) and WSSinner (p = 0.949) between before and after ASA.

Correlation between the difference in hemodynamic parameters and severity of HOCM before and after ASA

As shown in Fig. 5a, the difference in LVOT PPG before and a week after ASA was significantly correlated with the difference in the phase count of vortex and helix flow in AAO before and a week after ASA (R = 0.79, p = 0.004). The difference in LVOT PPG before and 6 M after ASA was also significantly correlated with the difference in the phase count of vortex and helix flow in AAO before and a week after ASA (Fig. 5b, R = 0.83, p = 0.002).

Interobserver variability

Interobserver variability of flow pattern in AAO (kappa = 0.75), duration of Vortex/Helix (ICC = 0.88), diastolic LV vortex area (ICC = 0.71), and the prevalence of systolic vortex (kappa = 0.73) were excellent.

Discussion

Our study focused on the differences in AAO and intra-LV flow evaluated by 4D flow MRI in drug-refractory HOCM before and after ASA. We demonstrated that ASA affected AAO flow and intra-LV flow patterns, and these changes were associated with the improvement of hemodynamics and alleviation of the symptoms.

4D flow MRI can visualize changes in hemodynamics of AAO and intra-LV, and previous studies have demonstrated a disease-specific flow pattern of AAO in valvular heart disease and cardiomyopathy [9, 11, 17]. However, there are few studies showing changes in hemodynamics of AAO and intra-LV after open-heart surgery or catheter intervention. ASA is an invasive treatment for drug-refractory HOCM to relieve heart failure symptoms and improve hemodynamics [18]. The improvement in NYHA class of heart failure, serum NT-proBNP levels, and SAM grade of mitral valve after ASA suggests the successful outcome of ASA in our study. TTE has been frequently used to evaluate the effect of ASA in patients with HOCM [15, 19–22]. TTE can show changes in LVOT PPG, degree of SAM, and septal thickness, but cannot show changes in AAO flow and intra-LV flow pattern. In the present study, the decreased incidence of the vortex and/or helix flow and the shorter duration of vortex or helix flow in the AAO, and a larger area in major vortex in the LV were observed. The decreased phase count of vortex or helix flow in AAO was associated with decreased LVOT PPG and helped in understanding the effect of ASA on systemic hemodynamics.

A considerable number of studies have assessed the hemodynamics of AAO in a bicuspid aortic valve (BAV) cohort using 4D flow MRI. The previously reported evidence included the derangement of flow pattern with the developed helical flow or eccentric flow, an increase of WSS, and abnormal tissue architecture in the dilated aortic wall according to increased WSS. These results suggest that 4D flow MRI-derived hemodynamic characteristics may be an additional diagnostic tool as an imaging biomarker for aortic valve disease and concomitant aortic dilation.

A previous study by Allen et al. [13] showed that there was higher grade helical flow in patients with HOCM compared with patients with non-obstructive HCM, and there was a significant correlation between helix grade and LVOT PPG. SAM of the mitral valve was associated with increased helix grade. These findings indicate that abnormal flow patterns in AAO can be observed in HOCM, which may be associated with LVOT PPG. However, in contrast to BAV, aortic dilation in HCM was rarely observed and had no relation with the extent of hypertrophy or LVOTO [23]. Another study also exhibited no significant difference in age-, sex-, and body surface area-adjusted norms of aortic size between patients with and without obstructive physiology in HCM [24]. Thus, the pathophysiological significance of the helical flow characteristics in terms of the impact on the non-dilated AAO wall in patients with HCM is uncertain [13].
Overall, abnormal flow patterns in AAO may be associated with the severity of HOCM, and any interventions to decrease LVOT PPG can also correct the flow pattern in AAO independent of aortopathy. However, the association has been published only in a single case report [25]. Although merely a speculation, the mechanism of AAO vortex or helix flow in HOCM appears to be the shift of outflow jet apart from the centerline of aorta producing the helix or vortex flow. As supporting evidence for this speculation, the significant association between the severity of aortic stenosis and severity of vortex and helix flow [10] as well as the mitigation of vortex and helix flow in BAV after aortic valve replacement [26] have been reported.

Other factors associated with aberrant flow in AAO include aortic stenosis and regurgitation [11] and aortic aneurysm [27]. Considering these previous reports, no subject in our study revealed aortic valve disease. Although the cause-effect relation with HCM is uncertain, four patients in our study had mildly dilated AAO with a diameter of > 40 mm. Interestingly, the duration of vortex or helix flow was mostly reduced after ASA even in these four patients (Table 4: cases 2, 7, 8, and 11). We expected a significant reduction in WSS after ASA with the decrease in LVOT PPG; however, we did not observe a significant change. Although it is only a speculation, the healthy aortic valve might have cleared the aberrant flow of HOCM in the AAO to some extent, inhibited the WSS elevation, and avoided the AAO dilatation.

Intra-LV vortex flow has been reported in some studies [17, 28, 29]. In general, the vortex ring is generated at the mitral valve tip in diastole with LV inflow [29]. In our study, the anterior side of the vortex ring grew and expanded into the LV as a major vortex in diastole (Fig. 4a and b). The large vortex in the dilated LV has been reported in some previous studies [17, 28].

---

### Table 5
Characteristics of blood flow in the left ventricle before and after ASA

| Case | Diastole | | Systole | |
|------|----------|----------|----------|----------|
| | Anterior vortex size, mm² | Posterior vortex size, mm² | | Prevalence of vortex above the LVOT | |
| | Before ASA | After ASA | Before ASA | After ASA | Before ASA | After ASA | Before ASA | After ASA |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 2920 | 0 | 2076 | 1 | 0 |
| 2 | 2679 | 3628 | 886 | 2750 | 1 | 1 |
| 3 | 0 | 0 | 3825 | 4146 | 0 | 0 |
| 4 | 3451 | 5463 | 458 | 380 | 0 | 0 |
| 5 | 2280 | 3270 | 333 | 616 | 1 | 0 |
| 6 | 0 | 0 | 0 | 0 | 1 | 0 |
| 7 | 1293 | 1424 | 0 | 0 | 0 | 0 |
| 8 | 1181 | 4166 | 1091 | 0 | 0 | 0 |
| 9 | 3894 | 3820 | 978 | 0 | 1 | 0 |
| 10 | 935 | 4679 | 0 | 354 | 0 | 0 |
| 11 | 2104 | 3345 | 592 | 610 | 0 | 0 |

ASA, alcohol septal ablation; LVOT, left ventricular outflow tract

### Table 6
Comparison of hemodynamic parameters in the ascending aorta and intra-LV

| Parameter | Before ASA | After ASA | P |
|-----------|------------|-----------|---|
| AAO Vortex | 11 (100%) | 8 (73%) | 0.083 |
| Helix | 5 (45%) | 4 (36%) | 0.564 |
| Vortex + Helix | 1.45 ± 0.52 | 1.09 ± 0.30 | 0.046 |
| Vortex area, mm² | 7317 ± 3964 | 6000 ± 4265 | 0.117 |
| Vortex/Helix duration, ms | 744 ± 291 | 467 ± 258 | < 0.001 |
| Vortex/Helix phase count, phases | 14.8 ± 4.4 | 10.5 ± 5.8 | < 0.001 |
| WSSouter, Pa | 1.15 ± 0.37 | 1.07 ± 0.56 | 0.575 |
| WSSinner, Pa | 0.88 ± 0.21 | 0.87 ± 0.37 | 0.949 |
| LV Diastolic anterior vortex area, mm² | 1628 ± 420 | 2974 ± 539 | 0.009 |
| Diastolic posterior vortex area, mm² | 458 (0–978) | 380 (0–2076) | 0.374 |
| Systolic LVOT vortex | 7 (63.6%) | 1 (9.1%) | 0.014 |

Data are expressed as mean ± standard deviation or median (interquartile range)

ASA, alcohol septal ablation; AAO, ascending aorta; LV, left ventricle; LVOT, left ventricular outflow tract; WSSouter, wall shear stress at outer curvature of ascending aorta; CIED, cardiac implantable electrical device; CMR, cardiac magnetic resonance; HOCM, hypertrophic obstructive cardiomyopathy; ICD, implantable cardioverter defibrillator; LVOTO: left ventricular outflow tract obstruction; MRI, magnetic resonance imaging; MVO, mid-ventricular obstruction; WSS, wall shear stress; WSSouter, wall shear stress at outer curvature of aortic arch; WSSinner, wall shear stress at inner curvature of aortic arch; PPG, peak pressure gradient
However, to the best of our knowledge, there is no previous report concerning the diastolic LV vortex in HOCM. Although the prevalence of diastolic intra-LV vortex was 100% in patients with preserved and impaired LV function in a previous study [17], it was 72.7% in the current study (Table 5). Compared to the study by Maron et al. [30], mitral valve was equally elongated in our cohort. Considering that the diastolic anterior vortex was generated at the tip of the mitral valve by flow separation, an elongated mitral valve leaflet in contact with the ventricular septum might attenuate the flow separation, resulting in a lower prevalence of diastolic intra-LV vortex. The other explanation is that the smaller LV cavity in HOCM might disturb the prevalence of the intra-LV vortex. Furthermore, we found a significant enlargement of the anterior vortex after ASA. The altered structure and chamber space in the LV cavity may restore the diastolic function, and reduced intra-LV and intra-LA pressure might change the LV inflow and subsequent vortex formation. Because the diastolic intra-LV vortex was considered efficient for preserving the hemodynamic energy [31], ASA might help in ameliorating the diastolic hemodynamic function in addition to improving the LVOTO. Although systolic rotational flow circulating the entire cavity of LV has been described in patients with impaired LV function [32], systolic vortex flow above LVOT has not been reported to date. Considering the significant decrease after ASA, systolic vortex flow just above LVOT and beneath aortic valve is probably associated with LVOTO and is a potential indicator for a favorable therapeutic effect.

The study limitations include the small sample size in the entire cohort and the lack of a control subject. Because the maximum flow velocity in the LVOT was elevated, 4D flow MRI was performed with relatively high VENC, which might have missed the blood flow with low velocity. The relatively low temporal resolution of 48 ± 6 ms could have missed the peak systole, resulting in an underestimation of peak flow velocity and WSS.

**Conclusions**

In conclusion, less vortex or helix flow in the AAO and larger diastolic vortex flow in the LV were observed after ASA using 4D flow MRI. The elucidation of hemodynamics in HOCM before and after ASA helps us to understand the association between pathophysiology and manifestation of the disease and suggests a potential for outcome prediction, resulting in improved patients’ management. Further investigation with a longitudinal study design and a larger sample size is warranted to verify the association between the improvement of aberrant hemodynamics and outcome after ASA in HOCM.

**Abbreviations**

%LGE: Fraction of late gadolinium enhancement to LV mass; 2D: Two-dimensional; 4D: Four-dimensional; 6 M: Six months; AAO: Ascending aorta; ASA: Alcohol septal ablation; BAV: Bicuspid aortic valve; CIED: Cardiac implantable electrical device; FA: Flip angle; FIESTA: Fast imaging employing steady-state acquisition; FOV: Field of view; FSPGR: Fast spoiled gradient recalled acquisition in the steady state; HCM: Hypertrophic cardiomyopathy; HOCM: Hypertrophic obstructive cardiomyopathy; ICC: Intraclass correlation coefficients; LAD: Left atrial dimension; LAVI: Left atrial volume index; LGE: Late gadolinium enhancement; LV: Left ventricle; LVEDD: Left ventricular end-diastolic dimension; LVEDVI: Left ventricular end-diastolic volume index; LVEF: Left ventricular ejection fraction; LVESD: Left ventricular end-systolic dimension; LVESVI: Left ventricular end-systolic volume index; LVMI: Left ventricular mass index; LVOT: Left ventricular outflow tract; LVOTO: Left ventricular outflow tract obstruction; LVSVI: Left ventricular stroke volume index; Max-IVST: Maximum...
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12872-021-02003-8.

Additional file 1: Table S1: Raw data for baseline characteristics, echocardiography, and cardiac MRI. The raw data from each patient are listed.

Additional file 2: Movie 1: Streamline movie of ascending aorta before ASA. In the ascending aorta, vortex flow in systole is followed by helical flow, which continues up to late diastole.

Additional file 3: Movie 2: Streamline movie of the ascending aorta a week after ASA. Although similar vortex flow in systole is observed, helical flow disappeared in early diastole at a week after ASA.

Additional file 4: Movie 3: Streamline movie of LV before ASA. Before the aorta, the streamlines exhibit relatively small vortex in LV at late diastole.

Additional file 5: Movie 4: Streamline movie of LV a week after ASA. The late diastolic vortex in LV became larger at a week after ASA compared to that before ASA.

Additional file 6: Movie 5: Streamline movie of LVOT before ASA. Before the aorta, the streamlines exhibit vortex flow above LVOT at peak systole.

Additional file 7: Movie 6: Streamline movie of LVOT after ASA. After ASA, the peak systolic vortex flow above LVOT disappeared.

Acknowledgements

Not applicable.

Authors' contributions

KS contributed to the study design, acquisition and analysis of data, and drafting of the manuscript. KA contributed to the acquisition and analysis of data. KT and TU contributed to the acquisition of data. YM contributed to the study design, drafting, and revising the manuscript. All authors read and approved the final manuscript.

Funding

This study received funding from the Ministry of Education, Science, Sports and Culture of Japan, Grants-in-Aid for Scientific Research (Grant Number 20277353 [KS]). The funding contributed to the data analysis and manuscript writing.

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article and its additional files.

Declarations

Ethics approval and consent to participate

This is a study involving human participants. This study was approved by the institutional review board (approval number 17–293). All patients provided written informed consent for participation.

Consent for publication

All the patients provided written informed consent for the publication.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Division of Cardiology, Internal Medicine 3, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Japan. 2 Department of Radiology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, 431-3192 Hamamatsu, Japan.

Received: 8 November 2020 Accepted: 5 April 2021

Published online: 20 April 2021

References

1. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348:295–303.
2. Autore C, Bernabò P, Barillà CS, Bruzzi P, Spirtoro P. The prognostic importance of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol. 2005;45:1076–80.
3. Elliott PM, Gimeno JR, Tomé MT, Shah J, Ward D, Thaman R, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J. 2006;27:1933–41.
4. Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46:470–6.
5. Soraja P, Valeyri U, Nishimura RA, Ommen SR, Rihal CS, Gersh BJ, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2008;118:131–9.
6. Veselka J, Jensen MK, Liebregts M, Januska J, Krejci J, Bartel T, et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Eur Heart J. 2016;37:1517–23.
7. Maekawa Y, Akita K, Takanashi S. Contemporaneous septal reduction therapy in drug-refractory obstructive hypertrophic cardiomyopathy. Cir J. 2018;82:1977–84.
8. Knight CJ. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Heart. 2006;92:1339–44.
9. Barker AJ, Markl M, Burk J, Lorenz R, Bock J, Bauer S, et al. Bicuspid aortic valve is associated with altered wall shear stress in the ascending aorta. Circ Cardiovasc Imaging. 2012;5:457–66.
10. von Knobelsdorff-Brenkenhoff F, Karunaharamoorthy A, Trauzeddel RF, Barker AJ, Blaszczyk E, Markl M, et al. Evaluation of aortic blood flow and wall shear stress in aortic stenosis and its association with left ventricular remodeling. Circ Cardiovasc Imaging. 2016;9:e004038.
11. Suwa K, Rahman OA, Bollache E, Rose MI, Rahnseap AA, Carr JC, et al. Effect of aortic valve disease on 3D hemodynamics in patients with aortic dilation and trileaflet aortic valve morphology. J Magn Reson Imaging. 2020;51:481–91.
12. Guzzardi DG, Barker AJ, van Ooij P, Malaisrie SC, Puthumana JJ, Belke DD, et al. Valve-related hemodynamics mediate human bicuspid aortopathy: insights from wall shear stress mapping. J Am Coll Cardiol. 2015;66:892–900.
13. Allen BD, Choudhury L, Barker AJ, van Ooij P, Collins JD, Bonow RO, et al. Three-dimensional haemodynamics in patients with obstructive and non-obstructive hypertrophic cardiomyopathy assessed by cardiac magnetic resonance. Eur Heart J. 2015;36:252–66.
14. Garcia J, Barker AJ, Markl M. The role of imaging of flow patterns by 4D flow MRI in aortic stenosis. JACC Cardiovasc Imaging. 2019;12:252–66.
15. Authors/Task Force members; Elliott PM, Anastasakis A, Borger MA, Borggreve M, Cecchi F, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733–79.
16. Raut M, Maheshwari A, Swain B. Awareness of systolic anterior motion in different conditions. Clin Med Insights Cardiol. 2018;12:1179546817751921.
17. Suwa K, Saitoh T, Takehara Y, Sano M, Saotome M, Urushida T, et al. Intra-left ventricular flow dynamics in patients with preserved and impaired left ventricular function: analysis with 3D cine phase contrast MRI (4D-Flow). J Magn Reson Imaging. 2016;44:1493–503.

18. Akita K, Tsuruta H, Yuasa S, Murata M, Fukuda K, Maekawa Y. Prognostic significance of repeated brain natriuretic peptide measurements after percutaneous transluminal septal myocardial ablation in patients with drug-refractory hypertrophic obstructive cardiomyopathy. Open Heart. 2018;5:e000786.

19. Soraja P, Binder J, Nishimura RA, Holmes Jr DR, Rihal CS, Gersh BJ, et al. Predictors of an optimal clinical outcome with alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Catheter Cardiovasc. Interv. 2013;81:E58–67.

20. Soraja P, Ommen SR, Holmes Jr DR, Dearani JA, Rihal CS, Gersh BJ, et al. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2012;126:2374–80.

21. Sanborn DMY, Sigwart U, Fifer MA. Patient selection for alcohol septal ablation for hypertrophic obstructive cardiomyopathy: clinical and echocardiographic evaluation. Interv Cardiol. 2012;4:349–59.

22. Veselka J, Duchohorova R, Palenickova J, Zemankov D, Tilienov M, Linhartov K, et al. Impact of ethanol dosing on the long-term outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy—a single-center, prospective, and randomized study. Circ J. 2006;70:1550–2.

23. Jain R, Helms A, Day SM, Booher AM. Prevalence of aortic dilation in hypertrophic cardiomyopathy. Am J Cardiovasc. Dis. 2013;3:79–85.

24. Geske JB, Nordhues BD, Orme NM, Tajik AJ, Spittell PC, Ommen SR. Prevalence and clinical correlates of aortic dilation in hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2021;34:279–85.

25. Suwa K, Akita K, Iguchi K, Sugiyama M, Maekawa Y. Improved blood flow after percutaneous transluminal septal myocardial ablation visualized by 4D flow cardiac magnetic resonance in a case of hypertrophic obstructive cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2018;19:1389.

26. Lenz A, Petersen J, Riedel C, Weinrich JM, Kooijman H, Schoennagel BP, et al. 4D flow cardiovascular magnetic resonance for monitoring of aortic valve repair in bicuspid aortic valve disease. J Cardiovasc Magn Reson. 2020;22:29.

27. Burkh J, Blanke P, Stankovic Z, Barker A, Russe M, Geiger J, et al. Evaluation of 3D blood flow patterns and wall shear stress in the normal and dilated thoracic aorta using flow-sensitive 4D CMR. J Cardiovasc Magn Reson. 2012;14:84.

28. Bermejo J, Benito Y, Alhama M, Yotti R, Martínez-Legazpi P, del Villar CP, et al. Intraventricular vortex properties in nonischemic dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2014;306:H718–29.

29. Martínez-Legazpi P, Bermejo J, Benito Y, Yotti R, Del Villar CP, González-Mansilla A, et al. Contribution of the diastolic vortex ring to left ventricular filling. J Am Coll Cardiol. 2014;64:1711–21.

30. Maron MS, Olivotto I, Harrigan C, Appelbaum CM, Lesser JR, et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation. 2011;124:40–7.

31. Cao Y, Sun X-Y, Zhong M, Li L, Zhang M, Lin M-J, et al. Evaluation of hemodynamics in patients with hypertrophic cardiomyopathy by vector flow mapping: comparison with healthy subjects. Exp Ther Med. 2019;17:479–88.

32. Suwa K, Saitoh T, Takehara Y, Sano M, Saotome M, Urushida T, et al. Intra-left ventricular flow dynamics in patients with preserved and impaired left ventricular function: analysis with 3D cine phase contrast MRI (4D-Flow). J Magn Reson Imaging. 2016;44:1493–503.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.